Logo

RXi

RXi Posts Flat Q3 Net Loss
Premium

NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week reported its third-quarter financial results, posting a net loss essentially flat with last year as expenses held steady.

RXi Q2 Losses Hold Steady
Premium

NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week reported its financial results for the second quarter, posting an unchanged net loss as expenses largely held steady from last year.

RXi Initiates Third Phase IIa Trial of Anti-scarring Drug
Premium

NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week announced that it has started a third Phase IIa trial for its anti-scarring treatment RXI-109.

Key RNAi Drugs in the Clinic: July 2014
Premium

NEW YORK (GenomeWeb) – With more interest from industry and investors than ever before, the RNAi therapeutics field has a record number of drug candidates in human testing for indications ranging from viral disease to cancer to skin disorders.

People in the News: Peter Campochiaro
Premium

RXi Pharmaceuticals has appointed Peter Campochiaro to its scientific advisory board.
May 15, 2014

RXi Q1 Loss Up on Slightly Higher Expenses
Premium

May 8, 2014

RXi Data Shows Anti-Scarring Drug Active in Non-human Primate Eyes
Premium

May 1, 2014

RXi Begins Second Phase IIa Trial of Anti-scarring Drug
Premium

Apr 24, 2014

Amid Biotech Downturn, Stocks of RNAi/microRNA Shops Hit Hard
Premium

Apr 24, 2014

RXi Inks Financing Arrangement with Lincoln Park Capital
Premium

Feb 20, 2014

RXi Regains Nasdaq Listing
Premium

Dec 19, 2013

With Drugs in the Clinic, Publicly Traded RNAi Firms See Gains in Market Caps
Premium

Nov 21, 2013

RXi Inks Deal to Sell Anti-scarring Drug in EU Prior to Approval
Premium

Nov 14, 2013

RXi Begins Phase II Trial of Anti-scarring Drug, Posts Q3 Results
Premium

Aug 15, 2013

RXi Reports Lower Q2 Loss, Expenses
Premium

Aug 8, 2013

As Investors Again Look to RNAi, Drug Developers Pull in More than $230M
Premium

Jul 25, 2013

RXi Files to Trade on the Nasdaq Once More
Premium

Jul 18, 2013

RXi Releases Phase I Data on Anti-Scarring Drug, Aims for Phase II This Year
Premium

Jun 27, 2013

RXi Shares Begin Trading on OTCQX Exchange
Premium

Jun 13, 2013

After Acquiring Opko Assets, RXi Aims to Resurrect Former Phase III AMD Drug
Premium

Jun 6, 2013

Phase I Data Shows RXi Anti-Scarring Drug Safe, Well-tolerated
Premium

May 16, 2013

RXi Q1 Loss Rises on Opko Deal Charge
Premium

Apr 25, 2013

People in the News: Paul Dorman, Curtis Lockshin
Premium

Apr 4, 2013

Following Private Placement, RXi Has Funds to Last into 2015
Premium

Mar 7, 2013

RXi Acquires Opko RNAi Assets, Inks Deals to Sell $16.4M in Stock
Premium

Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.